洛铂联合卡培他滨治疗蒽环类和紫杉类化疗失败的晚期乳腺癌的临床观察

目的探讨洛铂联合卡培他滨治疗蒽环类和紫杉类化疗失败的晚期乳腺癌的疗效及不良反应。方法36例蒽环类和紫杉类化疗失败的晚期乳腺癌患者，给予洛铂联合卡培他滨化疗：洛铂30mg／m^2，d1；卡培他滨每日2500mg／m。，分2次口服，d1～d14,3周为1周期。2周期后按wHO标准评价疗效及不良反应。结果36例患者均可评价疗效及不良反应，其中获CR2例，PR11例，SD12例，PD11例，有效率为36．1％，疾病控制率为69．49／6。主要不良反应为骨髓抑制和消化道反应，以1、2级为主，经对症处理后均可耐受。结论洛铂联合卡培他滨治疗蒽环类和紫杉类化疗失败的晚期乳腺癌的疗效较好，不良反应可耐受。

Clinical observation of lobaplatin combined with capecitabine for advanced breast cancer patients after the treatment failure of anthracycline and taxne

Objective To investigate efficacy and toxicity of lobaplatin combined with capecit- abine for advanced breast cancer patients after the treatment failure of anthracycline and taxne. Methods A total of 36 patients with advanced breast cancer were treated with lobaplatin（30mg/ m2,iv,d1） and capecitabine[2500mg/（m2·d）,po, d1-d14]. Three weeks was a cycle. The effica- cy and toxicity were evaluated by WHO standards after 2-cycle treatment. Results The efficacy and toxicity could be evaluated in all patients with 2 of CR, 1 of PR,12 of SD and 11 of PD. The response rate was 36.1~ and the disease control rate was 69.4~. The main side effects were myelosuppression and gastrointestinal reaction, mainly 1-2 degree, and could be well-tolerated. Conclusion Lobaplatin combined with capecitabine for advanced breast cancer patients after the treatment failure of anthracycline and taxne is effective and well tolerated.